Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
By Colin Kellaher
Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company.
Fulcrum on Monday said it will work with Sanofi on the development and commercialization of losmapimod, which is currently in Phase 3 studies for the treatment of facioscapulohumeral muscular dystrophy, a chronic and progressive disorder characterized by significant muscle cell death and fat infiltration into muscle tissue.
Fulcrum said it will receive an up-front payment of $80 million from Sanofi and will be eligible to receive up to an additional $975 million in regulatory and sales-based milestones.
The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights.
Fulcrum said it will received tiered escalating royalties starting in the low teens on sales of losmapimod outside the U.S., adding that the two companies will equally share future global development costs of the drug.
Fulcrum said it expects to report top-line data from its Phase 3 study of losmapimod by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 06:37 ET (10:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations